Myocardial Revascularization Trials.

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Cardiac Surgery

Background:

• Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are primary revascularization strategies for left main and multivessel coronary artery disease.
• Recent trials have compared the efficacy and safety of PCI versus CABG, yielding complex and sometimes debated results.

Purpose of the Study:

• To critically review the evidence from recent myocardial revascularization trials comparing PCI and CABG.
• To analyze potential biases in trial design, patient selection, and endpoint selection that may influence the interpretation of results.
• To provide recommendations for the cautious interpretation of current evidence and the design of future clinical trials.

Main Methods:

• Systematic review and critical appraisal of published data from major randomized controlled trials.
• Analysis of trial methodologies, including patient inclusion/exclusion criteria and outcome definitions.
• Synthesis of evidence to evaluate the comparative effectiveness of PCI and CABG in specific patient subgroups.

Main Results:

• The claimed noninferiority of PCI in certain patient groups (e.g., non-diabetic, low anatomic complexity) may be influenced by trial design.
• Patient selection favoring suitability for PCI and endpoint optimization potentially skewed results favoring PCI over CABG.
• Evidence suggests CABG may still offer superior long-term outcomes in specific complex patient populations.

Conclusions:

• A circumspect interpretation of current evidence comparing PCI and CABG is warranted.
• Future trials should prioritize robust design, unbiased patient selection, and appropriate endpoints to accurately reflect comparative effectiveness.
• Collaborative efforts in trial design and conduct are essential for advancing knowledge in cardiovascular interventions.